Shanghai YingLi Pharmaceutical Co. Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Shanghai China (2011)

Organization Overview

First Clinical Trial
2017
NCT03757000
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Shanghai YingLi Pharmaceutical Co. Ltd. | Yingli Pharma US, Inc | YL-Pharma

Active Ingredients

Drugs in Phase 2 Trials (6)

pe0105 (1 trial)

pe0116 (1 trial)

sintilimab (1 trial)

yl-13027 (3 trials)

yl-15293 (2 trials)

yy-20394 (11 trials)

Drugs in Phase 1 Trials (3)

camrelizumab (1 trial)

hy-0102 (1 trial)

yl-17231 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 1)

Lymphoma, T-Cell, Peripheral (Phase 1)

Neoplasms (Phase 1)

Waldenstrom Macroglobulinemia (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 21
  • # of Trial APIs: 9